Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stock Watch: Pandemic Lessons For Smaller Commercial Biotechs

Neurocrine And Clovis Are Still Deep In Pandemic Pressures

Executive Summary

Recently launched branded drugs prescribed by specialist physicians and marketed by smaller commercial-stage biotech companies remain in the eye of the pandemic storm.

You may also be interested in...



Stock Watch: Rollercoaster For Pfizer; Doldrums For Esperion

An early high for Pfizer with its strong first-quarter results was followed by patent waiver worries. At the other end of the spectrum, Esperion reminded us of the challenges in making a commercial success as a small biopharma firm in the pandemic.

Stock Watch: A Short History Of Placebo Approvals

Biogen’s recent contentious approval put the cat amongst the pigeons in the debate on surrogate markers as a basis for accelerated approval. The history of such approvals goes back to the last century.

Stock Watch: Post-Pandemic Life Science Market Dynamics

Factors in addition to the rejuvenation of pharmaceutical revenues and biotechnology product failures are likely to pull in opposite directions at the sector’s recovery from the pandemic.

Topics

Related Companies

UsernamePublicRestriction

Register

SC144406

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel